A safe and effective male birth control is edging closer to reality with new research pointing to an existing, temporary-acting drug’s potential.
Scientists had not found the right biological target for a safe reversible male birth control, which is why so few options have made it to human testing.
Women shoulder most of the weight of contraception, with half of women currently using one form of contraception, including pills, implants and intrauterine devices (IUDs). These methods come with a laundry list of side effects ranging from weight gain and mood changes to blood clots.
Now, researchers believe they have zeroed in on a brief, specific stage in sperm production where a drug could temporarily shut down fertility — and then, once stopped, let everything return to normal.
Researchers already knew that JQ1 — a drug that blocks a sperm-production protein called BRDT — worked as a contraceptive in mice. What is new is the detailed evidence showing exactly why it works, how the body bounces back, and precisely where in sperm production a future male pill should target.
By mapping out the molecular and genetic recovery in fine detail, the team has created a roadmap for a safe, reversible, hormone-free male contraceptive.
The challenge for developing male birth control has always been timing the drug’s effect within sperm production. Target stem cells at the very beginning of the process, and you risk permanent infertility. Target fully formed sperm at the very end, and some may still be functional enough to cause pregnancy.
The middle phase offers a natural checkpoint specific enough to block sperm formation but early enough that stem cells remain intact and ready to restart.
Half of women currently use contraception, including pills, implants and IUDs, all carrying side effects from weight gain and mood changes to blood clots (stock)
‘We’re practically the only the group that’s pushing the idea that contraception targets in the testis are a feasible way to stop sperm production,’ Dr Paula Cohen, corresponding author and genetics professor in the Cornell University College of Veterinary Medicine, said.
Researchers wanted to figure out if a safe target for male contraception could be meiosis, the phase in sperm production where chromosomes pair up, swap genetic material and then separate into individual sperm cells
The researchers gave male mice a daily injection of a drug called JQ1 for three weeks. The drug blocks a key protein called BRDT that only turns on during sperm production.
After treatment, they measured sperm counts, testicle size and whether the mice could still father offspring.
They also looked at individual cells under a microscope and used advanced genetic sequencing to see which genes were turned on or off.
After three weeks of daily JQ1 injections, the male mice were infertile — unable to get females pregnant. Their testicles shrank, their sperm counts plummeted and inspection of testicular tissue revealed that sperm development, while progressing through the early stages, had stalled out.
The cells were making it to the point where they should have become mature sperm, and then stopped.
The researchers confirmed this by looking at gene activity. The normal ‘transcriptional burst’ that happens during a specific phase of meiosis had been silenced.
Figure B shows testis mass as a percentage of body mass after three weeks of JQ1 treatment. Treated mice (T) showed a significant reduction in testis size compared to untreated (UC-T) and vehicle controls (VC-T). Figure C shows testis mass as a percentage of body mass six weeks after stopping JQ1 treatment. Recovery mice (R) showed testis mass comparable to untreated (UC-R) and vehicle (VC-R) controls, indicating full restoration
After stopping the drug, they waited six weeks and measured sperm counts, testicle size, chromosome pairing and gene activity.
The basics, including testis size and sperm counts, returned to normal, and the mice could father offspring again, though the first litters were smaller.
But when the researchers looked closer, they found lingering problems. The genetic crossover points, where chromosomes exchange DNA, a critical step for healthy sperm, had not fully recovered.
Some sperm still looked misshapen under the microscope, with bent flagella and abnormal heads, and certain gene programs related to sperm energy and movement remained disrupted.
Those deeper measures took significantly longer to heal, about 30 weeks or seven months.
Only then did those genetic crossovers, gene activity and sperm shape become indistinguishable from untreated mice.
Even though some molecular and structural aspects of sperm took much longer to fully normalize, this delay did not translate into fertility problems or birth defects in offspring. The mice eventually healed completely and their babies were healthy.
By comparing treated mice to untreated mice at every step — after treatment, at six weeks, at 30 weeks and in the next generation – they could see exactly what broke during drug treatment and whether it truly returned to normal.
Figure L shows that after three weeks on JQ1, reated mice (T) showed a significant reduction in developing sperm cells compared to untreated (UC-T) and vehicle controls (VC-T). Figure M shows that six weeks after stopping the drug, developing sperm cells had returned to normal levels. Recovery mice (R) showed ratios comparable to untreated (UC-R) and vehicle (VC-R) controls
Most of those things did, though a few took longer.
Eventually, they reported in the Proceedings of the National Academy of Sciences, everything returned to normal.
For decades, the search for a male birth control pill has been something of a scientific pipe dream.
The biology is generally more difficult to crack. Women release one egg per month, a predictable cycle.
Men produce hundreds of millions of sperm daily, around 1,500 every heartbeat. Shutting down this factory without killing libido, causing permanent infertility, or triggering nasty side effects turned out to be a much larger endeavor.
After decades of starts and stalls with constant barriers to success, including painful injections, spikes in cholesterol, mood swings and unpredictability.
A pill version never materialized and major pharmaceutical companies had abandoned the male contraceptive space in the 1990s altogether.
Unintended pregnancies account for nearly 44 percent of all pregnancies worldwide, and the burden has fallen almost entirely on women.
Current male contraceptives are limited to condoms and vasectomies. Many men are wary of vasectomies, the only long-acting option (stock)
Surveys consistently show that most men would welcome a reversible contraceptive option, with roughly 60 percent to 75 percent of men globally reporting willingness to use them. Currently, male contraceptives include condoms and vasectomies.
Many men are wary of vasectomies, the only long-acting option available to men. While the procedure is technically reversible through a second surgery, reversal is expensive and not always successful.
‘So we were really motivated to look for non-hormonal contraceptive targets in the testis, something that stops sperm production without affecting male libido and secondary sex characteristics,’ Cohen said.
Recent advances in genetics and cell biology have opened new paths that did not exist twenty years ago.
Instead of flooding the body with hormones, researchers are now targeting the sperm production process itself, finding precise molecular switches that exist only in the testis.
While the drug is not ready for humans — it has significant side effects, including immune suppression, weight loss at higher doses, potential neurological effects, and broader toxicity concerns — it serves as a proof of concept; an ability to avoid using hormones at all.
